Targeting lymphoma cells and their microenvironment with novel antibodies.
Novel monoclonal antibodies are currently being evaluated and have been shown to have significantly influenced the treatment of Hodgkin's and non-Hodgkin's lymphoma. It is of the utmost importance to reduce treatment-related toxicity and, hopefully, improve the cure rate of lymphoma. This is possible by using novel therapies such as monoclonal antibodies, which target tumor cells while sparing normal cells. Investigational antibody therapies include those targeting malignant cells as well as those targeting the microenvironment. Continued investigation is encouraged to combine monoclonal antibodies with other targeted therapies and incorporate their use into standards of care in the treatment of lymphoma.
Wedgwood
Amanda
A
Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Younes
Anas
A
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000096:biosynthesis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D008223:Lymphoma / Q000276:immunology* / Q000628:therapy*; D008954:Models, Biological; D016499:Radioimmunotherapy / Q000379:methods; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20